use of NT-pro BNP to detect kidney failure after liver transplantatio
Not Applicable
- Conditions
- Health Condition 1: K721- Chronic hepatic failure
- Registration Number
- CTRI/2021/06/034332
- Lead Sponsor
- Institute of liver and biliary sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Adult patients (18-65 years) with decompensated cirrhosis undergoing living donor liver transplant at Institute of Liver and Biliary Sciences.
Exclusion Criteria
Patient refusal.
Paediatric patients.
Patients with severe cardiac disease. [EF <45%, with regional wall motion abnormalities, asymmetric septal hypertrophy (septal/free wall ratio >1:3), Atrial Fibrillation with rapid ventricular response ( >100 beats/min)].
Acute liver failure.
Patients with recent H/o AKI ( <30 days), CKD and on Renal replacement therapy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assess the ability of NT-pro-BNP to predict early AKI after LDLTTimepoint: upto 7 days post liver transplant
- Secondary Outcome Measures
Name Time Method To assess the relationship between perioperative NT-proBNP level with postoperative morbidity (duration of mechanical ventilation, ICU and hospital length of stay, cardiac events). <br/ ><br>2. Correlation of perioperative NT-ProBNP with cirrhotic cardiomyopathy and postoperative cardiac dysfunction. <br/ ><br>3. Comparison of NT-ProBNP with established markers of AKI (serum cystatin C and urine NGAL). <br/ ><br>Timepoint: Baseline, 24 hours after surgery, preop 2d echo (within 3 months) and post transplant 2d echo within 7 days.